David Gjertson
Overview
Explore the profile of David Gjertson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bergersen K, Zheng Y, Rossetti M, Ruffin F, Pickering H, Parmar R, et al.
BMC Infect Dis
. 2025 Feb;
25(1):231.
PMID: 39966757
Background: Staphylococcus aureus bacteremia (SAB) is a prevalent life-threatening infection often caused by methicillin-resistant S. aureus (MRSA). Up to 30% of SAB patients fail to clear infection even with gold-standard...
2.
Locke A, Hickey M, Valenzuela N, Butler C, Sosa R, Zheng Y, et al.
Transplantation
. 2023 Sep;
107(10):e274.
PMID: 37749817
No abstract available.
3.
Lichtenstein B, Zheng Y, Gjertson D, Ferbas K, Rimoin A, Yang O, et al.
Front Immunol
. 2023 Jul;
14:1197326.
PMID: 37398658
Introduction: Severe COVID-19 illness is characterized by an overwhelming immune hyperactivation. Autoantibodies against vascular, tissue, and cytokine antigens have been detected across the spectrum of COVID-19. How these autoantibodies correlate...
4.
Sigdel T, Boada P, Kerwin M, Rashmi P, Gjertson D, Rossetti M, et al.
PLoS One
. 2023 May;
18(5):e0285870.
PMID: 37205661
Background: Cytomegalovirus (CMV) infection, either de novo or as reactivation after allotransplantation and chronic immunosuppression, is recognized to cause detrimental alloimmune effects, inclusive of higher susceptibility to graft rejection and...
5.
Locke A, Hickey M, Valenzuela N, Butler C, Sosa R, Zheng Y, et al.
Transplantation
. 2023 Mar;
107(8):1776-1785.
PMID: 36944607
The "virtual" crossmatch (VXM) has become a critical tool to predict the compatibility between an organ donor and a potential recipient. Yet, nonstandardized laboratory practice can lead to variability in...
6.
Ahn R, Schaenman J, Qian Z, Pickering H, Groysberg V, Rossetti M, et al.
Front Immunol
. 2021 Dec;
12:750659.
PMID: 34867983
Cytomegalovirus (CMV) viremia continues to cause significant morbidity and mortality in kidney transplant patients with clinical complications including organ rejection and death. Whole blood gene expression dynamics in CMV viremic...
7.
Butler C, Hickey M, Jiang N, Zheng Y, Gjertson D, Zhang Q, et al.
Am J Transplant
. 2020 Mar;
20(10):2768-2780.
PMID: 32185871
We analyzed humoral immune responses to nonhuman leukocyte antigen (HLA) after cardiac transplantation to identify antibodies associated with allograft rejection. Protein microarray identified 366 non-HLA antibodies (>1.5 fold, P < ...
8.
Mba Medie F, Sharma-Kuinkel B, Ruffin F, Chan L, Rossetti M, Chang Y, et al.
Proc Natl Acad Sci U S A
. 2019 Sep;
116(40):20087-20096.
PMID: 31527248
The role of the host in development of persistent methicillin-resistant (MRSA) bacteremia is not well understood. A cohort of prospectively enrolled patients with persistent methicillin-resistant bacteremia (PB) and resolving methicillin-resistant...
9.
Aziz N, Detels R, Quint J, Gjertson D, Ryner T, Butch A
BMC Immunol
. 2019 Sep;
20(1):33.
PMID: 31521107
Background: Cytokines, chemokines, adipocytokines, soluble cell receptors, and immune activation markers play an important role in immune responsiveness and can provide prognostic value since they reflect underlying conditions and disease...
10.
Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer
Zhu Y, Smith D, Zhou Y, Li Y, Yu J, Lee D, et al.
Cell Stem Cell
. 2019 Sep;
25(4):542-557.e9.
PMID: 31495780
Invariant natural killer T (iNKT) cells are potent immune cells for targeting cancer; however, their clinical application has been hindered by their low numbers in cancer patients. Here, we developed...